Gene · 8744
Papers3,166
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
641 to 660 of 3,166
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Releasing the restraints of Vγ9Vδ2 T-cells in cancer immunotherapy. | Front Immunol | 2022 | 36713444 | PubTator, text mining | PubMed |
| PRRSV-1 induced lung lesion is associated with an imbalance between costimulatory and coinhibitory immune checkpoints. | Front Microbiol | 2022 | 36713151 | PubTator, text mining | PubMed |
| Cell death-related biomarker SLC2A1 has a significant role in prognosis prediction and immunotherapy efficacy evaluation in pan-cancer. | Front Genet | 2022 | 36712872 | PubTator, text mining | PubMed |
| PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers. | Front Genet | 2022 | 36699446 | PubTator, text mining | PubMed |
| Construction and validation of a prognostic model for hepatocellular carcinoma: Inflammatory ferroptosis and mitochondrial metabolism indicate a poor prognosis. | Front Oncol | 2022 | 36686830 | PubTator, text mining | PubMed |
| Construction of a ferroptosis scoring system and identification of LINC01572 as a novel ferroptosis suppressor in lung adenocarcinoma. | Front Pharmacol | 2022 | 36686701 | PubTator, text mining | PubMed |
| The relevance between hypoxia-dependent spatial transcriptomics and the prognosis and efficacy of immunotherapy in claudin-low breast cancer. | Front Immunol | 2022 | 36685583 | PubTator, text mining | PubMed |
| The Role of Alternative Splicing Factors, DDB2-Related Ageing and DNA Damage Repair in the Progression and Prognosis of Stomach Adenocarcinoma Patients. | Genes (Basel) | 2022 | 36672781 | PubTator, text mining | PubMed |
| Identification of immune-related genes and development of a prognostic model in mantle cell lymphoma. | Ann Transl Med | 2022 | 36660618 | PubTator, text mining | PubMed |
| High SERPINH1 expression predicts poor prognosis in lung adenocarcinoma. | J Thorac Dis | 2022 | 36647484 | PubTator, text mining | PubMed |
| Construction and Validation of a Novel Immune Checkpoint-Related Model in Clear Cell Renal Cell Carcinoma. | Dis Markers | 2022 | 36618968 | PubTator, text mining | PubMed |
| Prediction of Survival and Tumor Microenvironment Infiltration Based on Pyroptosis-Related lncRNAs in Pancreatic Cancer. | Dis Markers | 2022 | 36618967 | PubTator, text mining | PubMed |
| Prediction of prognosis and immunotherapy response of amino acid metabolism genes in acute myeloid leukemia. | Front Nutr | 2022 | 36618700 | PubTator, text mining | PubMed |
| Prognostic and Immunological Implications of FAM72A in Pan-Cancer and Functional Validations. | Int J Mol Sci | 2022 | 36613817 | PubTator, text mining | PubMed |
| Combination of Expanded Allogeneic NK Cells and T Cell-Based Immunotherapy Exert Enhanced Antitumor Effects. | Cancers (Basel) | 2022 | 36612246 | PubTator, text mining | PubMed |
| Pan-Cancer Landscape of NEIL3 in Tumor Microenvironment: A Promising Predictor for Chemotherapy and Immunotherapy. | Cancers (Basel) | 2022 | 36612106 | PubTator, text mining | PubMed |
| Establishment of a prognostic prediction system based on tumor microenvironment of pancreatic cancer. | Medicine (Baltimore) | 2022 | 36595826 | PubTator, text mining | PubMed |
| Integrated bioinformatics analysis of IFITM1 as a prognostic biomarker and investigation of its immunological role in prostate adenocarcinoma. | Front Oncol | 2022 | 36591519 | PubTator, text mining | PubMed |
| In or out of control: Modulating regulatory T cell homeostasis and function with immune checkpoint pathways. | Front Immunol | 2022 | 36591244 | PubTator, text mining | PubMed |
| mRNA vaccines for cancer immunotherapy. | Front Immunol | 2022 | 36591226 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8744/papers?page=33